EAM
BNTC icon

Empery Asset Management’s Benitec Biopharma BNTC Stock Holding History

Empery Asset Management’s Portfolio BNTC Stock Details BNTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-30,440
Closed -$324K – 34
2026
Q1 		$324K Sell
30,440
-25,000
-45% -$289K 0.39% 17
2025
Q4 		$747K Buy
+55,440
New +$767K 0.66% 17
2022
Q3 		$296K Buy
+46,873
New +$596K 1.76% 16

Other funds holding BNTC

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IAM
Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return

Empery Asset Management's BNTC Position: Q2 2026 in Review

Empery Asset Management sold out of Benitec Biopharma (BNTC) in Q2 2026, closing a stake of 30,440 shares — an estimated $324K sold.

Empery Asset Management first reported a position in BNTC in Q3 2022 and held it in 3 quarters. The position peaked at $747K in Q4 2025. 86 funds tracked by Wall St. Rank hold BNTC as of Q2 2026.

  • Empery Asset Management reported no remaining Benitec Biopharma position as of Q2 2026 after selling out during the quarter.
  • Empery Asset Management sold 30,440 Benitec Biopharma shares in Q2 2026, an estimated $324K.
  • Empery Asset Management first reported a position in Benitec Biopharma in Q3 2022 and held it in 3 quarters.
  • Empery Asset Management's Benitec Biopharma position peaked at $747K in Q4 2025.
  • 86 funds tracked by Wall St. Rank held Benitec Biopharma as of Q2 2026.

Based on Empery Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.